017
EDCTP

European & Developing Countries

Clinical Trials Partnership

09:30-17:05 on Monday, 22 May 2017 & 09:00-15:10 on Tuesday, 23 May 2017 NH Hotel - meeting room TBD The Hague, the Netherlands Agenda

Agenda for the EDCTP General Assembly (GA) of 22-23 May 2017

The sequence of the items may be changed at the start of the meeting.

DAY 1 – EDCTP Association GA meeting 09:30-17:05 on Monday, 22 May 2017					
TIME	AGENDA	APPENDIX	SPEAKER	PURPOSE	
09:00 - 09:30	Coffee/Tea				
1.0 Welcome b	y the Chairperson				
09:30 - 09:35	1.1 Introduction by the Chairperson	х	Mark Palmer	Information	
09:35 - 09:40	1.2 Approval of the agenda	X	Mark Palmer	APPROVAL	
09:40 – 09:45	1.3 Approval of the minutes of the GA of 4-5 November 2016	х	Mark Palmer	APPROVAL	
09:45 – 09:50	1.4 Status of actions arising from the GA of 4-5 November 2016	х	Michael Makanga	Information	
2.0 Election of	Board (CLOSED SESSION)				
09:50 - 10:00	2.1 Brief Introduction	?	Louwrens Kiestra	Information	
10:00 - 10:10	2.2 Election of Board members	?	Michael Makanga	ELECTION	
10:10 - 10:25	2.3 Election of the Board Chairperson	?	Michael Makanga	ELECTION	
10:25 – 10:35	2.4 Election of the Board Vice- Chairperson(s)	?	Michael Makanga	ELECTION	
3.0 Updates from	om GA Observers				
3.1 European C	Commission				
10:35 – 10:50	3.1 Update from the European Commission	-	Line Matthiessen	Information	
10:50 – 11:05	Coffee/Tea				
4.0 Discussion	on EDCTP2 mid-term evaluation				
11:05 – 11:25	4.1.1 HR's response to mid-term evaluation	-	Leonardo Simao	Information/ discussion	
11:25 – 11:35	4.1.2 WHO-AFRO response to mid-term evaluation	-	Martin Ota	Information/ discussion	
11:35 – 12:35	4.1.3 GA discussion on recommendation	_	Mark Palmer	Discussion	

member states activities



09:30-17:05 on Monday, 22 May 2017 & 09:00-15:10 on Tuesday, 23 May 2017

NH Hotel - meeting room TBD The Hague, the Netherlands

European & Developing Countries Clinical Trials Partnership

Discussion

Agenda Clir

12:35 – 13:05 4.1.4 GA discussion on next steps on Mark Palmer

13:05 - 13:45 Lunch

5.0 Governance Matters

5.1 EDCTP Internal Regulations				
13:45 – 14:15	5.1.1 Updated Internal Regulations	X	Michael Makanga	APPROVAL
14:15 – 14:35	5.1.2 Establishment of Granting Committee	х	Michael Makanga	Discussion/ APPROVAL
5.2 EDCTP Asso	ociation Membership			
14:35 – 15:00	5.2.1 Adherence to membership requirements	-	Ole Olesen/ Moses Bockarie	Information/ discussion
15:00 – 15:20	See below (6.1.1, 6.1.2)			
5.3 Declaration of Liability				
15:20 – 15:35	5.3.1 Update from the Chairperson of the GA WG on the declaration of liability	Х	Mark Palmer	Information/ discussion

15:35 – 15:50 Coffee/Tea

6.0 EDCTP Constituencies

19:00	Dinner at Italian restaurant Taormina			
17:00 – 17:05	6.2.2 Membership	-	Michael Makanga	APPROVAL
16:40 – 17:00	6.2.1 Feedback from the SAC meeting of 30-31 March 2017	X	Catherine Hankins	Information
6.2 Scientific A	dvisory Committee (SAC)			
16:25 – 16:40	6.1.5 Update on EDCTP 2016 Annual Report		Michael Makanga	Discussion/ APPROVAL
16:15 – 16:25	6.1.4 EDCTP annual report 2016 to EC		Michael Makanga	Information
15:50 – 16:15	6.1.3 General updates	-	Michael Makanga	Information
15:00 – 15:10 15:10 – 15:20	6.1.1 Annual statutory accounts for 20166.1.2 Independent auditor's report	-	Abdoulie Barry Steven Spiessens	APPROVAL APPROVAL
6.1 Executive S	Secretariat, Board and Audit Committee			



09:30-17:05 on Monday, 22 May 2017 & 09:00-15:10 on Tuesday, 23 May 2017 NH Hotel - meeting room TBD The Hague, the Netherlands Agenda

European & Developing Countries Clinical Trials Partnership

DAY 2 – EDCTP Association GA meeting 09:00-15:10 on Tuesday, 23 May 2017

03:00-15:10 Or	i Tuesday, 23 May 2017				
TIME	AGENDA	APPENDIX	SPEAKER	PURPOSE	
7.0 EDCTP2 Work Plans					
09:00 – 09:20	7.1 EDCTP work plan 2014-2016: analysis of proposals	Х	Pauline Beattie	Information	
09:20 – 09:30	7.2 EDCTP2 work plan 2017	X	Ole Olesen	APPROVAL, pending EC approval	
09:30 – 10:00	7.3 New developments in implementation of EDCTP2 programme:7.3.1 Three year planning cycle and		Michael Makanga	Information/ Discussion	
	overall calls of activities over the remaining part of EDCTP2	x			
	7.3.2 New funding instrument: Portfolio funding	Х			
10:00 – 10:45	7.4 EDCTP2 work plan 2018: 7.4.1 Presentation (15 min) 7.4.2 Discussion (30 min)	X	Ole Olesen / Moses Bockarie	Discussion	
10:45 - 11:00	Coffee/Tea				
11:00 – 11:20	7.5 Analysis of PSIAs 2014-2016	Х	Gabrielle Breugelmans	Information	
11:20 – 11:30	7.6 Participating States Initiated Activities (PSIAs) reporting to the EC	-	Line Mathiessen	Information/ discussion	
11:30 – 11:50	7.7 Update and lessons learnt from PSIAs workshop	-	GA Rep from FR, DE and AT	Information/ discussion	
11:50 – 12:50	7.8 GA PSIAs discussion	-	All	Discussion	
12:50 - 13:45	Lunch				
8.0 Meetings and Events					
13:45 – 13:55	8.1 Stakeholder meeting on co- infections and co-morbidities	х	Pauline Beattie	Information	
13:55 – 14:05	8.2 Engagement with stakeholders and attendance at external meetings and events	-	Gabrielle Breugelmans/ Moses Bockarie	Information	
14:05 – 14:25	8.3. EDCTP Forums 2018 and 2020	х	Moses Bockarie	Discussion/ decision	
	8.3.1 Venues European Countries8.3.2 Venues African Countries	x	Host Countries	Information/ discussion	

F D C T P

09:30-17:05 on Monday, 22 May 2017 & 09:00-15:10 on Tuesday, 23 May 2017 NH Hotel - meeting room TBD The Hague, the Netherlands Agenda

European & Developing Countries Clinical Trials Partnership

9.0 Wrap-up and closing remarks

14:25 – 15:00 9.1 Any other business - Mark Palmer / All Information/

discussion

15:00 – 15:10 9.2 Date of next meeting & closing - Mark Palmer Information

remarks